Nat Prod Sci.  2016 Dec;22(4):282-286. 10.20307/nps.2016.22.4.282.

The Preventive and Curative Effect of Cyanidin-3β-D-Glycoside and Its Metabolite Protocatechuic Acid Against TNBS-induced Colitis in Mice

• Jang SE
• Choi JR
• Han MJ
• Kim DH

• KMID: 2366697
• DOI: http://doi.org/10.20307/nps.2016.22.4.282

Abstract

Cyanidin-3β-D-glycoside (C3G), which is widely distributed in herbal medicines and functional foods, exhibits anti-inflammatory, anti-oxidant, and anti-scratching behavioral effects. Orally administered C3G is metabolized to protocatechuic acid (PA) by gut microbiota. Therefore, we compared the anti-colitic effect of C3G to that of PA in mice with 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis. Orally administered C3G and PA preventively and curatively ameliorated TNBS-induced colitis parameters, including macroscopic colitis score, colon shortening, and increase of myeloperoxidase activity. Treatment with C3G or PA also inhibited the expression of cyclooxygenase-2, inducible NO synthatase, IL-1β, IL-6, and TNF-α and the activation of NF-κB in the colon of mice with TNBS-induced colitis. Furthermore, these also inhibited lipopolysaccharide-induced NF-κB activation and TNF-α expression in peritoneal macrophages. The anti-colitic effect of PA was more effective than C3G. Orally administered PA more potently attenuate colitis than C3G by inhibiting NF-κB activation and the anti-colitic efficacy of C3G may be dependent on the biotransformation of C3G to PA by gut microbiota.

Keyword

Colitis; Cyanidin-3β-D-glycoside; Procatechuic acid

MeSH Terms

Animals
Biotransformation
Colitis*
Colon
Cyclooxygenase 2
Functional Food
Gastrointestinal Microbiome
Interleukin-6
Macrophages, Peritoneal
Mice*
Peroxidase
Cyclooxygenase 2
Interleukin-6
Peroxidase

Figure

• 

  Fig. 1. The structures of C3G and PA.

• 

  Fig. 2. Experimental protocol. (A) Preventative effect for TNBS-induced colitis in mice. (B) Curative effect for TNBS-induced colitis in mice.

• 

  Fig. 3. The preventive effects of C3G and PA on TNBS-induced colitis in mice. (A) Effects on body weight. (B) Effects on colon length. (C) Effects on macroscopic colitis score. (D) Effects on colonic MPO activity. (E) Effects on TNF-α, IL-1β, and IL-6 expression. (F) Effects on COX2 expression. TNBS, except normal group (NOR, treated with vehicle alone), was intrarectally administered. Test agents (CON, vehicle alone; C10, 10 mg/kg; C20, 20 mg/kg; PA, 10 mg/kg; SS, 20 mg/kg sulfasalazine) were orally administered from the 3rd day before TNBS treatment to the 3rd day after TNBS treatment and sacrificed 18 h after the final administration of test agents. All values are means (n = 10). #P < 0.05, significantly different vs. normal group; ∗P < 0.05, significantly different vs. control group.

• 

  Fig. 4. The curative effects of C3G and PA on TNBS-induced colitis in mice. (A) Effects on body weight. (B) Effects on colon length. (C) Effects on macroscopic colitis score. (D) Effects on colonic MPO activity. (E) Effects on TNF-α, IL-1β, and IL-6 expression. (F) Effects on COX2 and iNOS expression and NF-κB activation. TNBS, except normal group (NOR, treated with vehicle alone), was intrarectally administered. Test agents (CON, vehicle alone; C10, 10 mg/kg; C20, 20 mg/kg; PA, 10 mg/kg; SS, 20 mg/kg sulfasalazine) were orally administered for 3 days after TNBS treatment and sacrificed 18 h after the final administration of test agents. All values are means (n = 10). #P < 0.05, significantly different vs. normal group; ∗P < 0.05, significantly different vs. control group.

• 

  Fig. 5. Effect of C3G and PA on NF-κB activation and TNF-α expression in LPS-stimulated peritoneal macrophages. Peritoneal macrophages (0.5 × 106 cells) were incubated with LPS in the absence or presence of C3G (C10, 10 μM; C20, 20 μM) or PA (P10, 10 μM) for 90 min (for NF-κB) or 20 h (for TNF-α). All data are shown as the mean ± S.D. (n = 3). #p < 0.05 vs. group treated without LPS and test agents. ∗p < 0.05 vs. group treated with LPS alone.

Reference

References

(1). He J.., Giusti M. M.Annu. Rev. Food Sci. Technol. 2010. 1:163–187.

(2). Han S. J.., Ryu S. N.., Trinh H. T.., Joh E. H.., Jang S. Y.., Han M. J.., Kim D. H. J.Food Sci. 2009. 74:H253–H258.

(3). de Ferrars R. M.., Czank C.., Zhang Q.., Botting N. P.., Kroon P. A.., Cassidy A.., Kay C. D.Br. J. Pharmacol. 2014. 171:3268–3282.

(4). Joseph S. V.., Edirisinghe I.., Burton-Freeman B. M. J.Agric. Food Chem. 2014. 62:3886–3903.

(5). Yang J.., Xiao Y. Y.Crit. Rev. Food Sci. Nutr. 2013. 53:1202–1225.

(6). Tsuda T.., Horio F.., Osawa T.Biofactors. 2000. 13:133–139.

(7). Min S.W.., Ryu S. N.., Kim D. H.Int. Immunopharmacol. 2010. 10:959–966.

(8). Vitaglione P.., Donnarumma G.., Napolitano A.., Galvano F.., Gallo A.., Scalfi L.., Fogliano V. J.Nutr. 2007. 137:2043–2048.

(9). Faria A.., Fernandes I.., Norberto S.., Mateus N.., Calhau C. J.Agric. Food Chem. 2014. 62:6898–6902.

(10). di Gesso J. L.., Kerr J. S.., Zhang Q.., Raheem S.., Yalamanchili S. K.., O'Hagan D.., Kay C. D.., O'Connell M. A.Mol. Nutr. Food Res. 2015. 59:1143–1154.

(11). Lee S. Y.., Jeong J. J.., Eun S. H.., Kim D. H.Eur. J. Pharmacol. 2015. 762:333–343.

(12). Ebert E. C.., Hagspiel K. D.Dig. Dis. Sci. 2011. 56:295–302.

(13). Wallace K. L.., Zheng L. B.., Kanazawa Y.., Shih D. Q.World J. Gastroenterol. 2014. 20:6–21.

(14). Laveti D.., Kumar M.., Hemalatha R.., Sistla R.., Naidu V. G.., Talla V.., Verma V.., Kaur N.., Nagpal R.Inflamm. Allergy Drug Targets. 2013. 12:349–361.

(15). Fairweather D.., Rose N. R.Lupus. 2005. 14:646–651.

(16). Dauphinee S. M.., Karsan A.Lab. Invest. 2006. 86:9–22.

(17). Perkins N. D.., Gilmore T. D.Cell Death Differ. 2006. 13:759–772.

(18). Tsuda T.., Horio F.., Osawa T. J.Nutr. Sci. Vitaminol. 2002. 48:305–310.

(19). Zhang Y.., Lian F.., Zhu Y.., Xia M.., Wang Q.., Ling W.., Wang X. D.Inflamm. Res. 2010. 59:723–730.

(20). Masella R.., Santangelo C.., D'Archivio M.., Li Volti G.., Giovannini C.., Galvano F.Curr. Med. Chem. 2012. 19:2901–2917.